Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul 158-710, Korea.
Division of Hemato-Oncology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul 158-710, Korea.
Korean J Radiol. 2014 Mar-Apr;15(2):300-4. doi: 10.3348/kjr.2014.15.2.300. Epub 2014 Mar 7.
Gefitinib is regarded as a relatively safe agent for the treatment of an advanced non-small cell lung cancer (NSCLC). Pulmonary toxicity such as interstitial lung disease associated with gefitinib is uncommon with an estimated all time incidence around 1% worldwide. Moreover, a case of gefitinib associated with pulmonary cystic changes has not been reported yet. In this report we present a case of progressive multiple air cystic changes in both lungs in a patient with NSCLC and intrapulmonary metastases who underwent a gefitinib therapy.
吉非替尼被认为是治疗晚期非小细胞肺癌（NSCLC）的一种相对安全的药物。吉非替尼相关的间质性肺病等肺部毒性并不常见，全球估计总发病率约为 1%。此外，尚未有报道吉非替尼与肺囊性改变相关。在本报告中，我们介绍了 1 例 NSCLC 伴肺内转移患者在接受吉非替尼治疗后出现进行性双侧肺部多发气腔囊性改变的病例。
